SCHEMBL12632897

SCHEMBL12632897

Cc1ccc(S(=O)(=O)Nc2cc(Cl)c(Sc3nc4cc(C)ccc4s3)c(Cl)c2)c(C)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 6/20 0.48
▸ HTT P42858 3/20 0.48
▸ KMT2A Q03164 4/20 0.45
▸ ALDH1A1 P00352 7/20 0.43
▸ MAPT P10636 6/20 0.43
▸ PKM P14618 4/20 0.43
▸ MEN1 O00255 3/20 0.43
▸ POLB P06746 3/20 0.43
▸ HPGD P15428 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ HSP90AA1 P07900 1/20 0.43
▸ HSP90AB1 P08238 1/20 0.43
▸ ALOX15 P16050 1/20 0.43
▸ ALOX12 P18054 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ TP53 P04637 3/20 0.42
▸ GAA P10253 2/20 0.42
▸ SMN1; SMN2 Q16637 3/20 0.42
▸ MAPK1 P28482 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12670142 0.92 MCL1 (0.51) LMNAHTTKMT2AALDH1A1MAPT
SCHEMBL2030698 0.82 LMNA (0.41) LMNAHTTKMT2AALDH1A1MAPT
SCHEMBL2038330 0.79 PPARG (0.43) LMNAHTTALDH1A1MAPTPOLB
SCHEMBL12670834 0.78 ALDH1A1 (0.46) LMNAHTTKMT2AALDH1A1MAPT
SCHEMBL2036572 0.78 CYP3A4 (0.49) LMNAKMT2AALDH1A1MAPTMEN1
SCHEMBL2033632 0.76 PPARG (0.45) LMNAKMT2AALDH1A1MAPTMEN1
SCHEMBL2031128 0.76 PPARG (0.48) LMNAKMT2AALDH1A1MAPTMEN1
SCHEMBL2034300 0.76 PPARG (0.45) MAPTPOLBGAACTSD
SCHEMBL2032951 0.75 PPARG (0.49) LMNAKMT2AALDH1A1MAPTMEN1
SCHEMBL2049721 0.75 PPARG (0.51) MAPTPOLBGAACTSD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7939551-B2 for diabetes mellitus and other metabolic disorders; compounds of given formula such as sulfonamides and an antidiabetic agent such as sulfonylureas, biguanides, glitazones, alpha-glucosidase inhibitors, glucagon antagonists AMGEN INC. (US) 2011-05-10 — — US disclosed
Send feedback